Oura's upcoming initial public offering represents the latest surge in investor interest for preventive healthcare wearables. However, justifying a mooted $16 billion valuation proves challenging. The Finnish-American maker of smart rings must secure more scientific endorsements to move beyond lifestyle gadget status.

Counterpoint Research estimates the wearable market could generate $1 trillion in cumulative sales by 2032, yet smart rings represent only a $44 billion slice compared to $300 billion-plus for watches and hearing devices. As healthcare costs soar, continuous monitoring's ability to flag issues between routine medical visits becomes increasingly valuable. Apple, Samsung, and Google's Fitbit have already received regulatory clearance for functions detecting arrhythmia, sleep apnea, and hypertension.

Once users accumulate months or years of data, switching barriers increase. Oura, a 13-year-old company, appointed its first chief medical officer last year and partners with Essence Healthcare, allowing eligible plan beneficiaries to receive rings with data monitored by doctors. Multiple clinical studies utilize Oura's data.

Despite these advances, valuation concerns persist. Even if Oura's EBITDA doubles, it would trade at 80 times forward earnings, compared to Apple and Garmin's 20 times. To align with larger peers, profit would need to triple over three years.

Furthermore, doctor skepticism remains; an American Medical Association survey found four-fifths of physicians use wearables but worry about legal liability and monitoring costs. Still, with two-fifths of new users attracted by word-of-mouth, Oura's community proves persuasive.